Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

That risk increased to 97% higher for people using systemic treatment. Cirrhosis and MASLD had the strongest associations with psoriasis. These findings are consistent with those from a 2022 study ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Psoriasis and psoriatic arthritis occur ... could inform clinical decisions and formulary policies regarding systemic treatment choices for older adults with psoriatic disease.